NASDAQ:RNA - Avidity Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.00
  • Forecasted Upside: 79.47 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$23.96
▲ +1.13 (4.95%)

This chart shows the closing price for RNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avidity Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNA

Analyst Price Target is $43.00
▲ +79.47% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $43.00, with a high forecast of $50.00 and a low forecast of $36.00. The average price target represents a 79.47% upside from the last price of $23.96.

This chart shows the closing price for RNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Avidity Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/7/2021Evercore ISIInitiated CoverageOutperform$50.00High
8/10/2021Credit Suisse GroupLower Price TargetOutperform$37.00 ➝ $36.00Low
6/17/2021Needham & Company LLCInitiated CoverageBuy$50.00Low
5/19/2021SVB LeerinkInitiated CoverageBuy$36.00Medium
7/7/2020SVB LeerinkInitiated CoverageOutperform$36.00N/A
7/7/2020CowenInitiated CoverageOutperformN/A
7/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$60.00N/A
7/7/2020Credit Suisse GroupInitiated CoverageOutperform$34.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/20/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Read More

Today's Range

Now: $23.96
Low: $22.78
High: $24.69

50 Day Range

MA: $21.09
Low: $18.16
High: $24.91

52 Week Range

Now: $23.96
Low: $17.58
High: $36.04

Volume

2,384,107 shs

Average Volume

509,983 shs

Market Capitalization

$902.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Avidity Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Avidity Biosciences in the last year: Credit Suisse Group AG, Evercore ISI, Needham & Company LLC, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for RNA.

What is the current price target for Avidity Biosciences?

4 Wall Street analysts have set twelve-month price targets for Avidity Biosciences in the last year. Their average twelve-month price target is $43.00, suggesting a possible upside of 79.5%. Evercore ISI has the highest price target set, predicting RNA will reach $50.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $36.00 for Avidity Biosciences in the next year.
View the latest price targets for RNA.

What is the current consensus analyst rating for Avidity Biosciences?

Avidity Biosciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RNA will outperform the market and that investors should add to their positions of Avidity Biosciences.
View the latest ratings for RNA.

What other companies compete with Avidity Biosciences?

How do I contact Avidity Biosciences' investor relations team?

Avidity Biosciences' physical mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company's listed phone number is 858-401-7900 and its investor relations email address is [email protected] The official website for Avidity Biosciences is www.aviditybiosciences.com.